Compare Recursion Pharmaceuticals Inc (RXRX) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Tapestry, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Tapestry, Inc. trades at $115.82 (market cap $23.09B). The key difference: Tapestry, Inc. is far larger — about 10.8× Recursion Pharmaceuticals Inc's market cap, and Tapestry, Inc. pays a 1.6% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Tapestry, Inc. for 70 Days on average.
| RXRX | TPR | |
|---|---|---|
Market Cap | $2.14B | $23.09B |
Volume | 30,789,535 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $164.78 |
52-Week Low | $2.84 | $98.81 |
Typical Hold Time | 22 Days | 70 Days |
Enterprise Value | $1.66B | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
TPR trades at $113.39, down 2.86% today, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 19.09% net income margin and 197.14% ROE, but net income fell sharply in 2025. Recent earnings beats and a $0.46 dividend highlight operational strength, while cash flow volatility and high debt-to-asset ratios pose concerns. Analyst consensus is strongly bullish with a $174.64 price target.
Outlook remains positive driven by international growth and margin expansion targets, but risks include execution challenges at Kate Spade, tariff pressures, and volatile cash flows. The stock offers value with a reasonable P/E of 15.6, though current price weakness near support at $113 may present a buying opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
